On the other hand, the future seems bright for selective Tyk2 inhibitors that maintain the safety profile of deucravacitinib and provide improved efficacy in psoriasis—perhaps comparable to that of biologic agents targeting the regulatory cytokine IL-23—and in other potential indications. Here, TYK2 is linked to psoriasis.